Molecular Diagnostic Firms Curetis And OpGen Announce Merger
The combination of the molecular diagnostic companies is structured as an acquisition of Curetis by OpGen. The merged companies will be a based in the US.
You may also be interested in...
Device financing increased substantially in Q3, thanks to debt raises led by Insulet. Acquisition dollar volume dropped, though, but Siemens' buy of Corindus for $1.1bn was a stand-out. Diagnostics/research tools financing dropped by 28% from Q2, while acquisition value greatly increased due to Exact Sciences' $2.8bn purchase of Genomic Health.
Currently available catheter-based devices for left-atrial appendage closure block the opening from the left atrium into the appendage, while Laminar’s innovative approach uses rotational motion to “eliminate” the LAA.
The American Medical Association has written a set of principles for augmented intelligence (AI) development and deployment in health care. The organization hopes these principles can shape “a consistent governance structure for advancements in health care technology.”